A140410 Stock Overview
Engages in the development, manufacturing, and sale of pharmaceutical products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Mezzion Pharma Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩33,850.00 |
| 52 Week High | ₩54,100.00 |
| 52 Week Low | ₩28,400.00 |
| Beta | 0 |
| 11 Month Change | -9.49% |
| 3 Month Change | -11.50% |
| 1 Year Change | -14.95% |
| 33 Year Change | -43.68% |
| 5 Year Change | -4.29% |
| Change since IPO | 241.34% |
Recent News & Updates
Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
Jun 11
Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking
Mar 04Recent updates
Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
Jun 11Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking
Mar 04We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon
Feb 05
Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain
Dec 14Shareholder Returns
| A140410 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.3% | 1.0% | 3.6% |
| 1Y | -14.9% | 7.3% | 2.5% |
Return vs Industry: A140410 underperformed the KR Pharmaceuticals industry which returned 7.3% over the past year.
Return vs Market: A140410 underperformed the KR Market which returned 2.5% over the past year.
Price Volatility
| A140410 volatility | |
|---|---|
| A140410 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A140410 has not had significant price volatility in the past 3 months.
Volatility Over Time: A140410's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 18 | Dean Park | www.mezzion.co.kr |
Mezzion Pharma Co.,Ltd. engages in the development, manufacturing, and sale of pharmaceutical products in South Korea. It is developing udenafil, a PDE5 protein for the treatment of erectile dysfunction, benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, and single heart failure diseases.
Mezzion Pharma Co.,Ltd. Fundamentals Summary
| A140410 fundamental statistics | |
|---|---|
| Market cap | ₩1.01t |
| Earnings (TTM) | -₩8.87b |
| Revenue (TTM) | ₩20.25b |
50.1x
P/S Ratio-114.3x
P/E RatioIs A140410 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A140410 income statement (TTM) | |
|---|---|
| Revenue | ₩20.25b |
| Cost of Revenue | ₩17.02b |
| Gross Profit | ₩3.22b |
| Other Expenses | ₩12.09b |
| Earnings | -₩8.87b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -296.23 |
| Gross Margin | 15.93% |
| Net Profit Margin | -43.80% |
| Debt/Equity Ratio | 0% |
How did A140410 perform over the long term?
See historical performance and comparison